Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer: 12-year follow-up of the multicentre, randomised controlled TME trial.
By W. van Gijn, C. Marijnen, I. Nagtegaal, E. Kranenbarg, Hein Putter, T. Wiggers, H. Rutten, L. Påhlman, B. Glimelius, C. J. van de Velde. The Lancet Oncology, 2011
1,731 citations recorded by the source corpus.
View Paper: https://www.semanticscholar.org/paper/777aa11099b8bcc2ae229a2d22923fa13571add9
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
Citations in the corpus
- Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years. (2012, neutral): “Although local control was consistently improved, none of these trials could show a significant improvement in overall survival.(9,11-13) Evidently, any improvement in overall survival rates will require better control of systemic disease.”
- The Applications of Radiomics in Precision Diagnosis and Treatment of Oncology: Opportunities and Challenges (2019, background): “Patients with rectal cancer usually undergo neoadjuvant chemoradiotherapy before surgery [164, 165], but it is not known whether pCR is achieved before neoadjuvant chemoradiotherapy.”
- Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2019 for the treatment of colorectal cancer (2019, methodology): “In the Dutch CKVO 95‐04 trial, which compared preoperative radiotherapy (25 Gy delivered in five fractions in one week) + TME and TME alone to investigate the significance of adding short‐course radiotherapy to TME, the 5‐year and 10‐year local control rates were signifi‐ cantly higher in the combin”